Vara builds AI-driven software to make breast cancer screening more accessible, reliable and affordable worldwide. The company develops a screening platform that integrates with the full screening pathway — from appointment booking and front-desk workflows to radiologist reads, lab reporting and follow-up — so healthcare providers can detect deadly breast cancers earlier and reduce unnecessary recalls and workload.

Vara combines state-of-the-art machine learning with clinical partnerships and real-world deployment. The platform is designed to keep radiologists in the loop while improving quality, capacity and patient outcomes.

Vara’s solutions are CE marked and certified under MDR. The company has partnered with leading research organisations and conducted the PRAIM prospective study in Germany (≈500k participants), producing peer-reviewed evidence of improved detection and workload reduction. Key milestones include a 2018 spin-off from Merantix, Series A funding led by OMERS, and international launches including India, Egypt and Mexico.